Stocks to Watch Battling
the Opioid Epidemic; Stocks Mentioned in this article: Greenlane
Holdings, Inc. (NASDAQ: $GNLN),
Safe Supply Streaming Co Ltd. (CSE: $SPLY.CN), Nutriband Inc. (NASDAQ: $NTRB), QuidelOrtho
Corporation (Nasdaq: $QDEL), Emergent BioSolutions Inc. (NYSE: $EBS)
September
20, 2024 - Investorideas.com, a
go-to investing platform covering cannabis stocks releases an industry snapshot
looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, Inc. (NASDAQ:GNLN), one of the premier global sellers of
premium cannabis accessories, child-resistant packaging, and specialty
vaporization products.
Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ:GNLN), Safe Supply Streaming Co Ltd. (CSE:
SPLY), Nutriband Inc. (NASDAQ:NTRB), QuidelOrtho Corporation (Nasdaq:
QDEL),
Emergent BioSolutions Inc. (NYSE:
EBS)
According
to Fact.MR ,“The
global opioid overdose treatment market is expected to reach a value of US$
1.54 billion in 2024, as revealed in a new industry analysis published by
proficient researchers at Fact.MR, a market research and competitive
intelligence provider. Revenue from the market is projected to increase at a
CAGR of 7.2% through 2034.”
Cannabis
company Greenlane Holdings,
Inc.
(NASDAQ:GNLN) has
entered the battle against dangerous drugs, but not only against opioids.
Greenlane announced this week its
plans to launch an all-new line of fentanyl, xylazine and drink spike detection
test strips under the Safety Strips, Inc.
brand of drug test strips. Products will be available to order beginning
September 25th via the Company's multiple online retail storefronts,
(vapor.com, puffitup.com, and higherstandards.com/) as well as its wholesale portal (wholesale.greenlane.com). Shipments will commence October 1st.
In August, Greenlane announced that it had
entered into a non-binding letter of intent to be the exclusive distributor in
the US of Safety Strips drug detection test strips. Greenlane has been a
trusted partner for some of the most successful and well-known cannabis and
lifestyle brands, such as Higher Standards, Marley Natural and K.Haring,
providing full sales coverage, marketing, warehousing and logistics services.
Paid news dissemination on behalf of GNLN
Read this article, featuring GNLN in full at https://www.investorideas.com/news/2024/cannabis/09201Battling-the-Opioid-Epidemic.asp
"We are delighted to be working with the
Safety Strips' team who share our high standards for safety and quality, and
our strong focus on improving people's lives and enhancing their safety,"
said Barbara Sher, Chief Executive Officer for Greenlane. "By combining
our extensive sales, marketing, and distribution network with Safety Strips ISO
13485 validated product line of easy, fast, and accurate test strips to detect
the presence of various drugs, we can do our part to help prevent accidental
overdoses as well as protecting individuals from drug-induced date rape."
The Opioid Epidemic in the United States
According to SHADAC.ORG, "Over the past two decades, the United
States has experienced a growing crisis of substance abuse and addiction that
is illustrated most starkly by the rise in deaths from drug overdoses. Since
2000, the annual number of overdose deaths from any kind of drug in the U.S.
has multiplied nearly six times over, rising from 17,500 to over 106,000 people
in 2021. The vast majority of these deaths (about 80,000) involved some form of
opioids, including heroin, prescription painkillers, and, most prevalently in
recent years, synthetic opioids such as fentanyl. Fentanyl and related
synthetic opioids alone accounted for roughly 71,000 drug overdose deaths in
2021, and are also involved in most methamphetamine, cocaine, and prescription
opioid overdose deaths-the next most common substances associated with overdose
deaths."
The Rising Incidence of Drink Spiking
In a January 2023 article posted on Alcohol.org, it was reported that "According to the
Office on Women's Health, date-rape drugs like Rohypnol, GHB, and ketamine are
used because they are not easily detected, and victims often do not remember
being drugged or assaulted until many hours later. In 2016, there were over
320,000 incidents of rape and sexual assault, and these incidents are often
underreported for both women and men. According to RAINN, 11.2 percent of
college students experience rape or sexual assault through force, violence, or
incapacitation, and in terms of drug-facilitated sexual assault, alcohol is the
No. 1 substance for assailants, next to prescription drugs with tranquilizing
effects and Rohypnol, ketamine, GHB, and ecstasy."
In response to the rising prevalence of drink
spiking, the Californian Assembly passed AB 1013, July 1, 2024. The bill
mandates that approximately 2400 establishments with a Type 48 license, which
allows the sale of beer, wine, and distilled spirits, must display signage
informing patrons that drug testing kits are available.The new law requires
businesses to display signs reading, "Don't get roofied! Drink spiking
drug test kits are available here. Ask a staff member for details."
Establishments must offer these drug testing devices either for sale or free of
charge.
Additionally, news
came out this week from Safe
Supply Streaming Co Ltd. (CSE: SPLY) noting it has made significant progress
within its portfolio through Safety Strips Inc. ("Safety Strips"), as
they introduce high-performing, reliable test strips designed to combat the rising
dangers of fentanyl, xylazine, and drink spiking.
This strategic initiative is expected to create
substantial value for Safe Supply shareholders, as the demand for safety and
drug testing continues to grow across North America. The product launch will
enter the market through the recently announced US Expansion Agreement with Greenlane Holdings, Inc. (NASDAQ:GNLN).
High Performing and Reliable Testing:
Safety Strips' product launch provides
consumers with an affordable, easy-to-use solution for detecting fentanyl and
xylazine - two substances contributing to the escalating opioid crisis. In
response to new California legislation, Safety Strips' Drink Spike Test strips
meet the requirements of California Assembly Bill No. 1013, passed in July
2024, which mandates that bars and clubs offer drug testing kits to their
patrons. The law is aimed at reducing incidents of drink spiking, a growing
safety concern in the hospitality industry.
Safety Strips' detection products will be
available for order starting September 25, 2024, across Greenlane's online retail platforms, with shipments
commencing on October 1, 2024.
This week Nutriband Inc. (NASDAQ:NTRB), announced a share repurchase program to buy back up to
$1,000,000 of its common stock. As of September 16, 2024, the Company had
11,106,185 shares of common stock outstanding. The stock spiked over 24% on the
news.
From the news:
Progress continues on the development of AVERSA Fentanyl, with the Company
maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025.
Nutriband Inc. is primarily engaged in the
development of a portfolio of transdermal pharmaceutical products. The lead
product under development is an abuse deterrent fentanyl patch incorporating
our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated
into any transdermal patch to prevent the abuse, misuse, diversion, and
accidental exposure of drugs with abuse potential.
Earlier this year,
QuidelOrtho Corporation (Nasdaq:
QDEL)
reported it has added the ARK™
Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as
well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip®
Partnership Assay ("MPA"). This Fentanyl assay will help hospital and
emergency room customers respond to the critical demand for enhanced opioid
testing, allowing on-site fentanyl testing in less than 10 minutes to aid in
immediate clinical decisions.
From the news: According to the Centers for Disease Control
and Prevention ("CDC"), the number of fatalities resulting from
fentanyl overdoses has tripled from 2016 to 2021, with an ongoing upward trend.
The CDC highlights California, Florida, New York, Pennsylvania and Ohio as
states with the highest mortality rates attributed to fentanyl.1 Consequently,
several states have responded by implementing regulations requiring fentanyl
testing to be included as a required component of drugs-of-abuse test panels.
"This assay
transforms laboratory efficiency by integrating fentanyl testing with existing
protocols to eliminate the need for external screening tests, and consolidates
a lab’s drugs-of-abuse panel into a singular, streamlined system, reducing
intervention time and ultimately helping to save lives," said Lily Li, Senior
Director of Medical and Clinical Affairs at QuidelOrtho. "Our relentless
commitment to diagnostics lies in empowering our customers with impactful
assays, particularly those capable of delivering rapid drugs-of-abuse detection
amidst the escalating opioid crisis."
From the news: Ninety percent of fentanyl is excreted as
norfentanyl, which is a synthetic opioid and is not detected on standard drug
screening. The ARK™ Fentanyl II Assay provides preliminary analytical test
results by detecting this major metabolite, reducing the risk of false
negatives. As part of QuidelOrtho’s Vitros systems’ menu of assays, the test
offers clinical fentanyl testing for hospitals and emergency departments,
providing an effective approach to preliminary urine drug testing.
From the news: Drug test results obtained in emergency
departments play a crucial role in addressing unique hospital challenges. When
patients test positive for opioids on a standard drug test, they’re usually
directed to drug treatment programs. However, these standard tests fail to
identify synthetic opioids, such as fentanyl. Without specifically testing for
fentanyl, instances of fentanyl exposure might be disregarded, potentially
leading to missed opportunities for life-saving interventions like
administering naloxone, an opioid overdose reversal medication.
Although the
pharmaceutical played a key role in opioid addiction, companies in the sector
are building out solutions.
Emergent BioSolutions
Inc. (NYSE: EBS) announced last month, the kicking off the second year
of the Ready to Rescue initiative, which will include new college football
tailgate stops, in-stadium activities, Greek Life events and student wellness
clinics. As part of these expanded efforts, pro football legend and campaign
spokesperson, Emmitt Smith, will continue to share his story to raise awareness
of opioid risks and inspire students, parents, faculty and alumni to be
prepared to save a life with NARCAN® Nasal Spray, which is available
over-the-counter (OTC).
The Centers for
Disease Control and Prevention (CDC) recently announced a reduction in drug
overdose deaths for the first time since 2018.1 However, opioid poisonings
continue to be the leading cause of accidental death in the United States,2
with the highest rate of opioid misuse and dependency among those 18 to 25.3
What’s more, research shows less than 15 percent of college students nationwide
know how to administer naloxone,4 the active ingredient in NARCAN® Nasal Spray,
which can reverse the effects of an opioid overdose, including those caused by
fentanyl. Education on the dangers of fentanyl, the signs of an opioid
poisoning and how to both access and administer NARCAN® Nasal Spray is vital to
saving lives, particularly within college communities.
According to Yale Medicine, “Fentanyl isn’t new; it has been used in the
U.S. since 1960 as an intravenous anesthetic. It is still prescribed today by
doctors, often in the form of patches and lozenges, for treating severe and
chronic pain from cancer and other illnesses and injuries.”
“But fentanyl has
shifted from exclusively being produced by pharmaceutical companies to now also
coming from drug cartels and other entities, says David Fiellin, MD, a Yale
Medicine primary care physician who specializes in addiction medicine.”
With news that the DEA
proposed rules last month to reclassify cannabis from a schedule I to a
schedule III substance, the shift can now really focus on dangerous drugs Greenlane Holdings, Inc. (NASDAQ:GNLN) has
the built-in marketing,
warehousing and logistics services to bring Safety Strips testing for dangerous
substances to the market.
More info in Greenlane Holdings visit here
Research more cannabis stocks with
Investor ideas free stock directory
https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform
for big investing ideas. From breaking stock news to top-rated investing
podcasts, we cover it all. Our original branded content includes podcasts such
as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye.
We also create free investor stock directories for sectors including mining,
crypto, renewable energy, gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news
article featuring GNLN is a paid for news
release on Investorideas.com. Our
site does not make recommendations for purchases or sale of stocks, services or
products. This is not investment
opinion: Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Global investors must adhere to regulations of each country.
Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact
Investorideas.com
800-665-0411
Cannabis Stocks- investing ideas in marijuana / hemp / cannabis / psychedelic stocks
Get more cannabis news, articles, podcasts and stock directories